Comparative Pharmacology
Head-to-head clinical analysis: LOTRISONE versus MENTAX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LOTRISONE versus MENTAX.
LOTRISONE vs MENTAX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Lotrisone combines betamethasone dipropionate, a corticosteroid that binds to glucocorticoid receptors, modulating gene expression to reduce inflammation, and clotrimazole, an imidazole antifungal that inhibits CYP51 (lanosterol 14alpha-demethylase), disrupting ergosterol synthesis and fungal cell membrane integrity.
Inhibits fungal squalene epoxidase, thereby blocking ergosterol biosynthesis and causing accumulation of squalene, leading to fungal cell death.
Apply a thin film to affected skin areas twice daily, morning and evening, for 2 weeks.
Butenafine hydrochloride 1% cream: apply to affected area once daily for 2 weeks for tinea pedis; for tinea corporis and tinea cruris, apply once daily for 1 week.
None Documented
None Documented
Clotrimazole: 3.5-6 hours (topical, minimal systemic absorption); betamethasone dipropionate: approximately 4-6 hours for betamethasone after hydrolysis.
Terminal elimination half-life is approximately 5-6 hours; clinical significance: supports twice-daily dosing for topical antifungal therapy.
Clotrimazole: <0.5% of dose excreted unchanged in urine; betamethasone dipropionate: primarily renal (<5% unchanged) and biliary/fecal (35-50% as metabolites).
Primarily fecal (biliary) as unchanged drug and metabolites; renal excretion of metabolites accounts for less than 1% of the dose.
Category C
Category C
Topical Antifungal/Corticosteroid Combination
Topical Antifungal